ArticleScientific reports2026
Integrative bioinformatics analysis unveils neuro-cancer crosstalk-related genes and establishes prognostic risk model in Glioblastoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuro-cancer crosstalk plays an important role in the development and progression of Glioblastoma (GBM), but its specific mechanisms remain incompletely elucidated. This study aims to systematically identify key genes related to neuro-cancer crosstalk in GBM and construct a prognostic risk model through integrating single-cell RNA sequencing (scRNA-seq), bulk RNA-seq, and machine learning algorithms. The GSE273274 dataset was obtained from the GEO database for single-cell data analysis to investigate differences in intercellular communication. GBM transcriptomic data were obtained from TCGA and GTEx databases for differential expression analysis, and WGCNA was used to identify co-expressed gene modules. LASSO Cox regression was employed to screen out key prognostic genes and construct a prognostic risk model. Immune infiltration, drug sensitivity analysis and molecular docking validation were conducted. Finally, the expression of key genes was validated through immunohistochemistry experiments. Single-cell analysis identified 15 cell types and revealed significantly elevated proportions of CD44+ astrocytes and oligodendrocyte progenitor cells in the GC group. Intercellular communication analysis showed key COL6A2-GP6 and L1CAM-ERBB3 interactions between pericytes and mature excitatory neurons. Transcriptomic analysis identified 6680 differentially expressed genes and 8636 WGCNA hub genes. Integrated analysis identified 7 key neuro-cancer crosstalk genes, among which NGFR and L1CAM were further selected to construct the prognostic risk model. This model demonstrated good predictive performance in both training and validation sets. Immune infiltration analysis showed significantly elevated M0 macrophage proportions in the high-risk group. GSEA analysis revealed enrichment of axon guidance and RAS-ERK signaling pathways in the high-risk group. Drug sensitivity analysis identified betamethasone acetate as a potential therapeutic agent, and molecular docking showed good binding capacity with L1CAM and NGFR. Immunohistochemistry confirmed high NGFR expression and low L1CAM expression in GBM. This study identified NGFR and L1CAM as potential key genes associated with neuro-cancer crosstalk in GBM through multi-omics integrated analysis, and demonstrated that the constructed prognostic risk model has utility for medium- to long-term survival prediction. The research findings provide new perspectives for understanding the mechanisms of neuro-cancer crosstalk in GBM and offer important theoretical foundations and potential targets for developing personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.